{
    "Trade/Device Name(s)": [
        "Emit II Plus Cocaine Metabolite Assay"
    ],
    "Submitter Information": "Siemens Healthcare Diagnostics Inc.",
    "510(k) Number": "K170293",
    "Predicate Device Reference 510(k) Number(s)": [
        "K993988"
    ],
    "Regulatory Class": "Class II",
    "Product Code(s)": [
        "DIO"
    ],
    "Summary Letter Date": "October 16, 2017",
    "Summary Letter Received Date": "October 17, 2017",
    "Submission Date": "October 24, 2017",
    "Regulation Number(s)": [
        "21 CFR 862.3250"
    ],
    "Regulation Name(s)": [
        "Cocaine and cocaine metabolite test system"
    ],
    "Analyte Class(es)": [
        "toxicology"
    ],
    "Analyte(s)": [
        "Benzoylecgonine"
    ],
    "Specimen Type(s)": [
        "Human urine"
    ],
    "Specimen Container(s)": [],
    "Instrument(s)/Platform(s)": [
        "Beckman Coulter DxC 700 AU Clinical Chemistry Analyzer",
        "number of chemistry analyzers"
    ],
    "Method(s)/Technology(ies)": [
        "Enzyme immunoassay"
    ],
    "Methodologies": [
        "Homogeneous enzyme immunoassay"
    ],
    "Submission Type(s)": [
        "Assay",
        "Reagent"
    ],
    "Document Summary": "FDA 510(k) summary for Emit II Plus Cocaine Metabolite Assay for qualitative and semiquantitative analysis of benzoylecgonine in human urine",
    "Indications for Use Summary": "For qualitative and semiquantitative analyses of benzoylecgonine (cocaine metabolite) in human urine at 150 or 300 ng/mL cutoffs; provides preliminary analytical test results on chemistry analyzers",
    "fda_folder": "Toxicology"
}